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Summary Diabetes mellitus affects 9% of the adult
population worldwide and the economic burden of
the disease is growing exponentially. In type 2 dia-
betes mellitus (T2DM), when life style interventions
fail to achieve treatment targets, oral antidiabetic
drugs are prescribed to improve glycemic control.
Several new oral antidiabetics have been launched
in the last few years, which enlarged the spectrum
of available treatment options in T2DM. The present
study aimed to examine T2DM treatment patterns
in a cohort of 7769 patients recruited from the Dia-
betes Registry Tyrol (DRT) with at least one visit from
2012–2015. Secondly, the study aimed to evaluate the
use of new oral antidiabetics compared to older oral
antidiabetics (OAD). It was found that 43.4% of all pa-
tients were treated with OAD alone while 21.2% had
oral antidiabetics combined with insulin. 19.9% of the
study population were treated with insulin or insulin
analogs only. 15.3% had no pharmacological treat-
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ment. Metformin was used most frequently (47.9% of
the study population), followed by gliptines (27.2%).
The most common treatment regimen in this popula-
tion was the dual therapy of metformin and another
OAD (17.2%), followed by metformin monotherapy
(16.6%) and triple therapy of metformin and two
additional OAD (11.0%).
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Introduction
Diabetes mellitus is one of the most prominent causes
of premature illness and death worldwide. Type 2 di-
abetes mellitus (T2DM) is characterized by increased
insulin resistance, depleted insulin secretion and sub-
sequently elevated levels of blood glucose. The T2DM
affects approximately up to 6.4% of adults in the gen-
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Table 1 Demographic and
clinical data in thediabetes
registryof Tyrol
Parameter Patients (n) Age (years, mean ± SDa) Frequency (%)
Sex
Male 3260 66.5 ± 12.9 42.0
Female 4509 64.2 ± 11.8 58.0
Total 7769 65.2 ± 12.3 100
Age groups (years)
18–39 207 – 2.7
40–59 2229 – 28.7
60–79 4418 – 56.9
80–99 915 – 11.8
Diabetes duration (years)
0–5 1824 – 29.8
5–10 1472 – 24.1
10–20 1999 – 32.7
20–99 822 – 13.4
Diabetes associated late complications
Nephropathy 705 – 15.4
Neuropathy 472 – 10.3
Myocardial infarction 470 – 10.3
Apoplectic insults 287 – 6.3
Peripheral artery disease 258 – 5.7
Retinopathy 103 – 2.3
aMean ± SD standard deviation
eral population; however, an estimated 50% of cases
of T2DM may still remain undiagnosed at present [1].
In Austria, T2DM is widespread and affects nearly
9% of the population, which accounts for 640,000
inhabitants [2]. Main treatment goals for T2DM are
to achieve near normal levels of blood glucose as
well as to avoid acute and long term complications,
among which hypoglycemia and hyperglycemia, dia-
betic nephropathy, diabetic retinopathy, and diabetic
neuropathy are the most common [2, 3].
Treatment strategies for T2DM comprise life style
modification, patient-centred education programs,
and pharmacological treatment options. The Amer-
ican Diabetes Association (ADA) and the European
Association for the Study of Diabetes (EASD) consen-
sus statements recommended glycated hemoglobin
A1C (HbA1c) levels <7% as being desirable for most
non-pregnant adults, due to the reduction of mi-
crovascular complications [4]; however, higher target
values of HbA1c may be advisable in the presence of
complications, age or comorbidities [5].
According to national and international guideline
recommendations, pharmacological treatment op-
tions are recommended when life style and education
programs fail to achieve HbA1c levels <6.5%. In the
absence of certain contraindications, oral antidiabetic
treatment with metformin should be initiated, due to
its favorable risk profile for hypoglycemic events, its
beneficial influence on body weight as well as due to
financial considerations. Treatment can be escalated
twice up to the use of three oral antidiabetic drugs
(OAD) or be combined with subcutaneous insulin
substitution. The OAD should be chosen according
to efficacy, side effects, patient-derived risk factors,
treatment targets and availability. Newer OAD, namely
glucagon-like peptide-1 (GLP-1) agonists and sodium-
glucose cotransporter 2 (SGLT-2) inhibitors have ex-
panded the spectrum of available treatment options
[3, 5–7]. Pharmacological treatment accounts for
a greater part of health economic costs related with
T2DM, besides treatment of complications, clinical
examination and absence from work due to compli-
cations.
The aim of the present study was to characterize the
current prescription patterns of antidiabetic drugs in
the region of Tyrol between 2012 and 2015; therefore,
data from the diabetes registry of Tyrol (DRT) were
analyzed in order to identify current developments of
the treatment of T2DM in a real life situation.
Patients and methods
The DRT was initiated in 2005 and includes relevant
data from approximately 17,000 patients with dia-
betes mellitus, 11,000 of which were diagnosed with
T2DM. The present analysis covers data from 7769
T2DM patients, who attended at least one T2DM-
related outpatient or inpatient visit between 1 Jan-
uary 2012 and 31 December 2015. The DRT records
demographic, anamnestic and clinical data of inci-
dent and prevalent T2DM patients. Relevant data
comprise age, sex, body mass index (BMI), HbA1c,
diabetes duration, diabetic long-term complications
(e.g. diabetic nephropathy, neuropathy, retinopathy
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Table 2 Therapies in the treatmentof type2diabetesmel-
litus in thediabetes registryof Tyrol
Class Frequency n (%)
Oral 5018 (64.6)
Metformin 3722 (47.9)
Gliptins 2114 (27.2)
Metformin or gliptins 4387 (56.5)
Glitazones 289 (3.7)
Glucosidase inhibitors 33 (0.4)
SGLT-2 inhibitors 291 (3.7)
Sulfonylurea analogues 1046 (13.5)
GLP-1 analogues 83 (1.1)
Insulin 1335 (17.2)
Insulin analogues 2569 (33.1)
Insulin or analogues 3193 (41.1)
Bariatric surgery 32 (0.4)
Life style intervention only 1190 (15.3)
Total 7769 (100.0)
SGLT-2 sodium-glucose cotransporter 2, GLP-1 glucagon like peptide-1
and macrovascular complications). Pharmacological
treatment has been recorded since 2012, including
substance class, start and end date of prescription.
The date of diagnosis of T2DM was known in 5827
patients (approximately 75%). For each patient, the
most recent examination was used for analysis be-
tween the year 2012 and 2015.
This study aimed to summarize antidiabetic med-
ication prescription in T2DM patients who partici-
pated in the DRT between the years 2012–2015. As the
current investigation did not aim to correlate or com-
pare any prescription patterns between participants,
no statistical tests were performed. Current prescrip-
tion patterns were illustrated using STATA statistical
analysis software, version 13 (StataCorp LP, College
Station, TX).
Results
Table 1 shows the demographic and clinical data of
T2DM patients, Table 2 illustrates prescription pat-
terns of OADs and insulin and Table 3 provides data
on age-dependent prescription patterns of OADs and
insulin. Table 4 shows data on insulin use in the DRT.
Of 7690 patients analyzed, 58% were female, 42%
were male and the mean age was 65.2 ± 12.3 years. Of
the patients 56.9% where in the age group 60–79 years,
28.7% were aged between 40–59 years, 11.8% were
older than 80 years and 2.7% were aged below
39 years. The mean BMI was 30.1 ± 6.1 kg/m2 and
mean HbA1c in the study population was 7.6% ± 1.44.
The most common diabetes duration was 10–20 years
(32.7%), followed by 0–5 years (29.8%) and 5–10 years
(24.1%). Least frequent in the DRT were patients with
a diabetes duration over 20 years (13.4%). Of the
diabetes associated late complications, nephropathy
was the most common (15.4%), followed by neuropa-
thy (10.3%) and myocardial infarction (10.3%). Less
common were apoplectic insults (6.3%), peripheral
artery disease (5.7%) and retinopathy (2.3%). Of all
the patients analyzed 85% received at least one type
of T2DM-related treatment other than lifestyle educa-
tion (pharmacological or surgical treatment). In 43.4%
of all patients OAD alone were used, followed by OAD
combined with insulin (21.2%), resulting in a total of
65% of patients who used at least one OAD. Single use
of insulin (classical insulin and insulin analogues) was
prescribed in 19.9% of all patients analyzed. Among
OADs prescribed in the DRT, metformin was the most
frequent (47.9%), followed by gliptines (27.2%), sul-
fonylurea analogues (13.5%), glitazones (3.7%), SGLT-
2 inhibitors (3.7%), GLP-1 analogues (1.1%) and glu-
cosidase inhibitors (0.4%). Metformin monotherapy
was used in 16.6% of all patients. Dual therapy (met-
formin + another OAD) was prescribed in 17.2% of
all patients. Among those, the combination with
gliptines (9.9%) was most common, followed by in-
sulin (or insulin analogues 5.3%), and sulfonylurea
analogues (2.0%). Triple therapy (metformin + 2 other
OADs and/or insulin) was used in 11% of all patients.
Among those, metformin plus gliptines plus another
OAD was used most frequently (6.5%).
Metformin was most frequently prescribed in
patients <60 years of age (55.1% in patients be-
tween 18–39 years and 60.5% in patients between
40–59 years). Older patients (≥60 years) had less
prescription of metformin (47% in patients between
60–79 years and 19.9% in patients ≥80 years). The sec-
ond most commonly prescribed OADs were gliptines,
which were used in 19.3% of patients between
18–39 years, in 29.3% of patients between 40–59 years,
28% of patients between 60–79 years and 20% in older
patients (≥80 years). The third most common OAD
group were sulfonylurea analogues, which were pre-
dominantly prescribed in older patients (≥80 years).
Newer treatment options (SGLT-2-inhibitors and GLP-
1-analogues) were prescribed more rarely and pre-
dominantly in patients between 18–39 years of age.
Use of insulin was more frequent in elderly patients
with a peak among patients ≥80 years (23.8%) and
15.3% of T2DM patients did not receive any treat-
ment except for education and life style modification.
Discussion
In the DRT, metformin, either alone or as part of
a combination therapy, was prescribed most fre-
quently, followed by gliptines. The most common
dual therapy was metformin plus gliptines, followed
by metformin plus insulin. Sulfonylureas were used
more frequently in older patients. Insulin therapy was
used in approximately half of all T2DM patients in the
DRT, newer OADs were used less frequently and more
in younger T2DM patients. The majority of T2DM pa-
tients in this cohort were treated with well-established
OADs but this may be explained by favorable safety
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Table 3 Therapies in the
treatmentof type2diabetes
mellitus in thediabetes reg-
istryof Tyrol byagegroups
Class 18–39 years,
n (%)
40–59 years,
n (%)
60–79 years,
n (%)
80–99 years,
n (%)
Oral 123 (59.4) 1592 (71.4) 2878 (65.1) 425 (46.4)
Metformin 114 (55.1) 1349 (60.5) 2077 (47.0) 182 (19.9)
Gliptins 40 (19.3) 653 (29.3) 1238 (28.0) 183 (20.0)
Metformin or gliptins 119 (57.5) 1467 (65.8) 2505 (56.7) 296 (32.3)
Glitazones 7 (3.4) 113 (5.1) 156 (3.5) 13 (1.4)
Glucosidase inhibitors – 13 (0.6) 14 (0.3) 6 (0.7)
SGLT-2 inhibitors 12 (5.8) 128 (5.7) 150 (3.4) 1 (0.1)
Sulfonylurea analogues 14 (6.8) 237 (10.6) 627 (14.2) 168 (18.4)
GLP-1 analogues 1 (0.5) 37 (1.7) 43 (1.0) 2 (0.2)
Insulin 27 (13.0) 304 (13.6) 786 (17.8) 218 (23.8)
Insulin analogues 44 (21.3) 613 (27.5) 1552 (35.1) 360 (39.3)
Insulin or insulin analogues 52 (25.1) 754 (33.8) 1908 (43.2) 479 (52.3)
Bariatric surgery 7 (3.4) 15 (0.7) 10 (0.2) –
Life style intervention only 54 (26.1) 342 (15.3) 643 (14.6) 151 (16.5)
Total 207 (100.0) 2229 (100.0) 4418 (100.0) 915 (100.0)
SGLT-2 sodium-glucose cotransporter 2, GLP-1 glucagon like peptide-1
Table 4 Insulin use in thediabetes registryof Tyrol
Treatment type Frequency n (%)
OAD without insulin 3370 (43.4)
OAD with insulin 1648 (21.2)
Insulin therapy only (classical and/or analogue) 1544 (19.9)
No therapy 1190 (15.3)
Total 7769 (100.0)
OAD
profiles and efficacy. On the other hand constraints
in reimbursement are still significant for some of the
newer OADs, which may impede the prescription in
an outpatient setting, even though scientific and clin-
ical knowledge encourage the prescription of newer
OADs.
Treatment strategies for T2DM vary worldwide
depending on the prescribed substances, reimburse-
ment regulations and lifestyle education, factors that
are likely driven by regional financial capacity and
epidemiological profiles. These international differ-
ences are most impressively illustrated by data from
recent epidemiological studies, which show that most
T2DM patients are living in developing or transition
countries [8, 9]. The increasing prevalence of T2DM
as well as the development of new OADs empha-
size the need for feasible and cost-efficient treatment
strategies in the long-term. Treatment guidelines vary
across different countries, making regular epidemi-
ological meta-analyses a reasonable tool of quality
assurance and adaption. Although reimbursement
regulations in most European countries allow a rela-
tively broad spectrum of available treatment options,
this does not apply for most non-European countries,
especially in terms of newer OADs. Patients may
be confronted with high retention fees, insufficient
supplies or restrictions in available treatment options.
The national diabetes report of the USA showed
that approximately 57% of all patients in 2014 were
treated with OADs alone, while approximately 15%
of all patients were given a combination of insulin
and OADs. Insulin monotherapy was established in
14% of the patients. Compared to data from the USA,
patients registered in the DRT were prescribed OADs
less often (44.3%), while the combination of OAD and
insulin was more common (21.2%). The most com-
monly prescribed OAD in the USA is currently met-
formin (used in approximately 50% of diabetes pa-
tients) [10, 11]. Over the years, partially influenced by
the development of newer medications, prescription
patterns have significantly changed. Since an anal-
ysis by Brouwer et al. [12] it was found that met-
formin prescription rates decreased from 60-70% in
2000 to current world-wide estimated rates of 45–50%
[8], which is in line with our results; however, met-
formin monotherapy was prescribed only in 17% in
the DRT compared to 53% in the USA [7]. A possible
explanation is frequent use of fixed dose combina-
tions (including metformin and another OAD) in the
DRT. Also, pharmacological second line treatments
(e. g. gliptines) are both less expensive and are re-
imbursed to a considerable amount by the healthcare
system. Moreover, metformin is contraindicated in
the presence of certain conditions and comorbidities,
such as nephropathy, which was manifest in 15.4%
of DRT patients. Another reason might be that the
use of metformin is associated with a considerable
frequency of adverse effects (including gastrointesti-
nal complaints) and was found to induce weight loss,
which may be limit the use for elderly, lean patients.
In our study population 27% of all patients had glip-
tine medication and 57%were treated with eithermet-
formin or gliptines, while gliptines were only used in
8–13% of patients in the USA. On the other hand,
sulfonylureas were used more frequently in the USA
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(23–27% of all T2DM patients), alone or as part of
a combination therapy. In the DRT, however, sulfony-
lureas were the third most common OADs (13%) and
were more frequently prescribed in older patients. In
principle, it might be expected that insulin use would
increase in older patients due to the longer duration
of disease; however, insulin treatment may impose
a challenge to older patients and their family mem-
bers or caretakers. Insulin is considered the most
effective and flexible therapy for T2DM but the ad-
verse event profile, especially the risk for severe hypo-
glycemia and the need for cognition and compliance,
make insulin a challenging treatment option for both
patients and prescribers. While initial insulin treat-
ment patterns in T2DM are relatively easy for com-
pliance, increasing demands of insulin often require
more complex strategies, such as multiple daily in-
jections, intensified self-assessment of blood glucose,
carbohydrate:insulin ratios; therefore, sulfonylureas
may be an attractive alternative to the more com-
plex and time-consuming insulin regimen. Insulin use
over the age groups increased by 27.2% compared to
an increase of sulfonylurea use of 11.6%; however, in
younger patients the lower prescription rates of sul-
fonylureas compared to gliptines may be explained
by the unfavorable risk profile and side effects [10, 13,
14]. The prescription of newer therapies, however, was
less frequent in DRT. After stratification of the cohort
by age and subsequent analyses, it was shown that
these treatments are more frequently given to younger
patients, which is in line with international data [7,
10]. The less frequent prescription of newer OADs
may be explained by their current prescription costs
and higher bureaucratic effort. For instance, treat-
ment costs for T2DM medications increased by 61%
due to the implemented use of insulin glargine and
gliptines in the USA.
The prevalence of diabetic late complications was
generally lower compared to data from the USA.
Among patients in the DRT, nephropathy was most
common (15.4%), followed by neuropathy (10.3%) and
myocardial infarction (10.3%). In the USA, nephropa-
thy is reported to occur in approximately 40% of
diabetes patients [15–17]. The prevalence of periph-
eral neuropathy is estimated to occur in 12–50% of
diabetic patients [18]; however, sufficient epidemio-
logical data from the USA are not available to date.
Therefore, the ADA reported prevalence rates refer
to European data [18]. In the DRT, myocardial in-
farction occurred in 10.3% and apoplectic insults in
6.3% of participants. The age-adjusted percentage
of people aged 35 years or older with diabetes and
with self-reported coronary heart disease (i. e. self-re-
ported coronary heart disease, angina or heart attack)
was more than two times that of self-reported stroke
(21.9% vs. 9.1%) [19]. The true prevalence of periph-
eral artery disease (PAD) is difficult to estimate due
to its coincidence with peripheral neuropathy, which
may mitigate pain perception and the high percent-
age of asymptomatic patients. Amputation has been
used as a measure for PAD; however, medical care
and local indications for amputation vary widely. The
current nationwide, age-adjusted amputation rate is
prevalent in 3% of US inhabitants. Retinopathy was
present in 2.3% of DRT participants. According to
data from the governmental National Eye Institute,
approximately 8.4% of diabetic patients in the USA
were diagnosed with some degree of retinopathy [20].
In conclusion, we found that metformin is the
most commonly prescribed OAD in the DRT, while
newer OADs are prescribed less frequently and more
in younger T2DM patients. Sulfonylureas are still
a popular option, especially in older T2DM patients.
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